U.S. infectious disease group backs Gilead’s remdesivir for COVID-19 treatment

The top U.S. infectious disease medical association said on Monday that Gilead Sciences Inc’s antiviral drug remdesivir should be used for hospitalized COVID-19 patients despite a World Health Organization (WHO) recommendation last week against its use.

Read the full article here

Related Articles